Signaling Pathway Activation After Exercise in Patients With Chronic Obstructive Pulmonary Disease (SIM)
|ClinicalTrials.gov Identifier: NCT01561625|
Recruitment Status : Completed
First Posted : March 23, 2012
Last Update Posted : May 7, 2013
Muscle weakness and atrophy are important consequences of chronic obstructive pulmonary disease (COPD). Although resistance exercises increase strength and muscle mass in patients with COPD, the response to training appears to be suboptimal in these individuals. A dysregulation in the signaling pathways involved in the regulation of muscle mass could play an important role in this phenomenon.
Hypothesis: Proteins involved in muscle mass regulation will be less activated in the quadriceps of patients with COPD following the acute bout of resistance training exercise compared to healthy age-matched controls.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Other: exercise||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Signaling Pathway Activation in the Quadriceps of Patients With COPD After an Acute Bout of Resistance|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||April 2013|
|Actual Study Completion Date :||April 2013|
- Other: exercise
resistance training exercise, 1 session, 3 exercises, 80% of max
- Post-exercise signaling proteins phosphorylation level in the quadriceps of COPD patients and age-matched healthy controls [ Time Frame: 2 hours post-exercise ]Phosphorylation status of key proteins (Akt, p70, mTOR, p38, JNK, ERK) will be lesser modulated in the quadriceps of patients with COPD compare to healthy controls. The phosphorylated as well as the total protein levels will be measured by western blot. The data will be presented as arbitrary units and compared with values obtained in healthy age-matched healthy controls.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561625
|Quebec City, Quebec, Canada, G1V 4G5|
|Principal Investigator:||François Maltais, MD||Laval University|